Analyzing Guardant Health (GH) and Its Competitors

Share on StockTwits

Guardant Health (NASDAQ: GH) is one of 24 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Guardant Health to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Guardant Health and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health 0 0 5 0 3.00
Guardant Health Competitors 178 637 745 46 2.41

Guardant Health currently has a consensus price target of $79.67, suggesting a potential upside of 7.63%. As a group, “Medical laboratories” companies have a potential upside of 15.77%. Given Guardant Health’s rivals higher possible upside, analysts clearly believe Guardant Health has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Guardant Health and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Guardant Health $90.64 million -$85.06 million -26.44
Guardant Health Competitors $1.13 billion $64.04 million -2.11

Guardant Health’s rivals have higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

69.5% of Guardant Health shares are held by institutional investors. Comparatively, 52.0% of shares of all “Medical laboratories” companies are held by institutional investors. 17.1% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Guardant Health and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardant Health N/A N/A N/A
Guardant Health Competitors -108.16% -113.88% -33.85%

Guardant Health Company Profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Anticipate BG Staffing Inc  to Post $0.30 EPS
Brokerages Anticipate BG Staffing Inc to Post $0.30 EPS
CoinFi 24-Hour Volume Tops $1,708.00
CoinFi 24-Hour Volume Tops $1,708.00
FLIP Hits Market Cap of $722,843.00
FLIP Hits Market Cap of $722,843.00
ChatCoin  24-Hour Volume Hits $396,693.00
ChatCoin 24-Hour Volume Hits $396,693.00
Helleniccoin Price Down 11.7% This Week
Helleniccoin Price Down 11.7% This Week
Ultrapar Participacoes  Share Price Crosses Above 50-Day Moving Average of $5.31
Ultrapar Participacoes Share Price Crosses Above 50-Day Moving Average of $5.31


 
© 2006-2019 Zolmax.